clinical trial · NCT04560166
Naxitamab and GM-CSF in Combination With IT in Patients With High-Risk Neuroblastoma
Neuroblastoma RecurrentNaxitamab and GM-CSF in combination with irinotecan and temozolomide
brief summary
An International, Single-Arm, Multicenter Phase 2 Trial.
started
Nov 8, 2021
primary completion
Sep 21, 2022
completion
Sep 21, 2022
last updated
Mar 18, 2024
detailed description
This is an international, single-arm, multicenter phase 2 trial, in patients ≥ 12 months of age with high-risk NB with primary refractory disease or in first relapse. Patients will receive naxitamab + GM-CSF + irinotecan/temozolomide. The Follow-Up period ends 2 years after End of Treatment.
official title
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor in Combination With Irinotecan and Temozolomide in Patients With High-Risk Neuroblastoma With Primary Refractory Disease or in First Relapse. An International, Single-Arm, Multicenter Phase 2 Trial.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol